Status:
UNKNOWN
Bonding, Self-effıcacy and Vital Signs in Infants Undergoing Cardiovascular Surgery
Lead Sponsor:
Istanbul University - Cerrahpasa
Conditions:
Mother-Infant Interaction
Eligibility:
All Genders
3-120 years
Phase:
NA
Brief Summary
Congenital heart diseases, the most common type of congenital anomalies, which affect approximately 3% of all live births and are the second most common cause of death in infants, are associated with ...
Detailed Description
Of the 130 million children born in the world each year, four million die in the neonatal stage. Congenital heart disease (CHD) is a serious congenital anomaly that can be seen at a rate of 5-8 per 10...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Born term,
- Those who have undergone CVS surgery and sternatomy
- Pediatric CVD intensive care unit patients
- Extubated
- Watched accompanied by his mother
- Can be breastfed by his mother
- Can be fed enterally
- No arrhythmia
- Clotting factors are within normal limits
- Baby and mother with 'Not at Risk' or PCR result 'Negative'
- Babies whose mothers accept the training and practice within the scope of the research.
- Exclusion Criteria
- Those with 'Risky' or PCR result 'Positive' baby and mother during follow-up
- Sudden weight loss or acute gastrointestinal system problems
- Babies who are at risk of bleeding and cannot feed (with chylothorax etc.)
- Extubated babies with risk of reintubation and respiratory distress
- Babies whose mothers leave them for various reasons.
Exclusion
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT06158373
Start Date
December 1 2020
End Date
March 1 2024
Last Update
December 6 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sirin Celik
Maltepe, Istanbul, Turkey (Türkiye)